Multiple sclerosis onset during etanercept treatment [6]

European Neurology

Volumn 59, Issue 1-2, 2007, Pages 91-93

  Gomez Gallego, Maria ^a   Meca Lallana, Jose ^a   Fernandez Barreiro, Andres ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYANOCOBALAMIN; DOUBLE STRANDED DNA; ETANERCEPT; FOLIC ACID; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; PREDNISONE;

ADULT; BLOOD LEVEL; CASE REPORT; CEREBROSPINAL FLUID; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LABORATORY TEST; LETTER; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; PSORIATIC ARTHRITIS; THORAX RADIOGRAPHY; TREATMENT DURATION; VISUAL ACUITY;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; METHYLPREDNISOLONE HEMISUCCINATE; MULTIPLE SCLEROSIS; PREDNISOLONE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37249090599     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109576     Document Type: Letter

References (25)

1. Renno T, Krakowski M, Piccirillo C, Lin JY, Owens T: TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis: regulation by Th1 cytokines. J Immunol 1995;154:944-953.
2. Cole P, Rabasseda X: The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease. Drugs Today (Barc) 2004;40:281-324.
3. Rieckmann P, Albrecht M, Kitze B, et al: Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
4. Van Oosten BW, Barkhof F, Scholten PE, von Blomberg BM, Ader HJ, Polman CH: Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis. Arch Neurol 1998;55:793-798.
5. Bitsch A, Kuhlmann T, Da Costa C, Bunkowski S, Polak T, Bruck W: Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 2000;29:366-375.
6. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M: Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994;24:2040-2048.
7. Selmaj KW, Raine CS: Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 1995;45(suppl 6):S44-S49.
8. Van Oosten BW, Barkhof F, Truyen L, et al: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-1534.
9. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group: TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-465.
10. Mohan N, Edwards ET, Cupps TR, et al: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-2869.
11. Sicotte NL, Voskuhl RR: Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-1888.
12. Enayati PJ, Papadakis KA: Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol 2005;39:303-306.
13. Thomas CW Jr, Weinshenker BG, Sandborn WJ: Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004;10:28-31.
14. FDA Briefing Document: Safety update on TNF-alpha antagonists: infliximab and etanercept. Rockville, FDA, 2001.
15. FDA Briefing Document: Update on the TNF-alpha blocking agents. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm (accessed 2003).
16. Noguera-Pons R, Borras-Blasco J, Romero-Crespo I, Anton-Torres R, Navarro-Ruiz A, Gonzalez-Ferrandez JA: Optic neuritis with concurrent etanercept and isoniazid therapy. Ann Pharmacother 2005;39:2131-2135.
17. Kunzmann S, Warmuth-Metz M, Girschick HJ: Cerebral demyelination in association with TNF-inhibition therapy in a 5-year-old girl with aseptic meningitis as the first symptom of Still's disease. Scand J Rheumatol 2005;34:76-78.
18. Freeman HJ, Flak B: Demyelination-like syndrome in Crohn's disease after infliximab therapy. Can J Gastroenterol 2005;19:313-316.
19. McDonald WI, Compston A, Edan G, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
20. Surtees R, Clelland J, Hann I: Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies. J Clin Oncol 1998;16:1505-1511.
21. Aladro Y, Alemany MJ, Perez-Vieitez MC, et al: Prevalence and incidence of multiple sclerosis in Las Palmas, Canary Islands, Spain. Neuroepidemiology 2005;24:70-75.
22. Kassiotis G, Pasparakis M, Kollias G, Probert L: TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur J Immunol 1999;29:774-780.
23. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ: Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995;377:348-351.
24. Midgard R, Gronning M, Riise T, Kvale G, Nyland H: Multiple sclerosis and chronic inflammatory diseases: a case-control study. Acta Neurol Scand 1996;93:322-328.
25. Heinzlef O, Alamowitch S, Sazdovitch V, et al: Autoimmune diseases in families of French patients with multiple sclerosis. Acta Neurol Scand 2000;101:36-40.